FDA Approves Tavapadon Across Parkinson Disease Stages

Company AbbVie Event Type FDA Approval Modality Small Molecule Asset Tavapadon (Juvmo) Target D1/D5 Dopamine Receptors Disease Area Parkinson’s Disease Summary The FDA approved AbbVie’s once-daily tavapadon, branded Juvmo, for adults with Parkinson’s disease with or without levodopa. The decision creates the first approved selective…